Developer docs
API playgroundTry for free, no card

Search company profiles

Engage Therapeutics

Full company profile

uuid0004kkg

Namestring
Engage Therapeutics
Legal namestring
UCB S.A.
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 and headquartered in Summit, New Jersey. The company is focused on developing therapeutic solutions for epilepsy, operating within the broader neurological and autoimmune drug development space. Per the firmographic data, Engage Therapeutics runs a deliberately lean organization of 1-10 employees, consistent with a venture-backed, asset-focused biotech structure.

The company was capitalized at founding by a $23.6 million venture financing closed in September 2017, led by TPG Biotech with participation from Adage Capital Management, Granite Point Capital, LifeSci Venture Partners, and Lumira Ventures. The founding executive team consists of Greg Mayes as President, CEO, and Founder, with Heath Lukatch serving as Chairman. The company remains privately held, and no commercial products, pricing, partnerships, or revenue figures specific to Engage Therapeutics are disclosed in the available input data.

Note on data hygiene: a substantial portion of the input aggregates material pertaining to UCB S.A., a publicly traded Belgian biopharmaceutical company with operations across dozens of countries. That material — including UCB's revenue disclosures, global footprint, Candid Therapeutics acquisition, UCBCares service, and sub-brand portfolio — describes a separate entity and is not attributable to Engage Therapeutics in this analysis.

Short descriptiontext

Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 in Summit, New Jersey, developing treatments for epilepsy. The privately held firm has raised $23.6M in venture capital led by TPG Biotech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSummit, United States
HQ citystring
Summit
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical stage pharmaceuticals, epilepsy drug development, neurology therapeutics, biopharmaceutical research, seizure treatment development
Industry1 code
PRIMARYHLAKAIAB
Epilepsy & Seizure Disorders
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Epilepsy Therapeutics
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1UCBCares
Description

A personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine

ucb.com
+2 more records
Core offering1 text field

Engage Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic drug candidates for epilepsy. The company focuses on advancing treatments for seizure management through clinical development of neurological therapies, operating from its Summit, New Jersey headquarters with a small team (1-10 employees).

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Epilepsy Clinical Development Program
CategoryNeurology Pharmaceuticals
Description

Clinical-stage drug development program advancing therapeutic candidates for the treatment of epilepsy and seizure-related neurological conditions. Targeted at patients living with severe seizure disorders; the program operates at a pre-commercial, clinical-stage phase with therapeutic candidates advancing through clinical development.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

UCB completed acquisition of Candid Therapeutics to strengthen its next-generation immunology pipeline. This strategic acquisition enhances UCB's immunology portfolio and research capabilities.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy and other neurological conditions. Comparable to Engage in therapeutic area and clinical development stage.

TypeDirect peer
Description

Clinical-stage CNS biopharmaceutical company focused on seizure disorders, including status epilepticus and rare epilepsies. Directly comparable to Engage in therapeutic area, development stage, and target patient population.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing transformative medicines for neurological diseases, with a focus on rare and severe epilepsies. Closely comparable to Engage in stage, therapeutic focus, and capital structure.

TypeBroad incumbent
Description

Global pharmaceutical company with a historical epilepsy franchise (e.g., Lyrica, Neurontin) and broad CNS capabilities. Comparable as a large pharma incumbent with neurology depth and acquirer potential.

TypeBroad incumbent
Description

Global biopharmaceutical leader with major epilepsy franchise (Vimpat, Keppra) and broad CNS pipeline. Comparable as a large incumbent in Engage's therapeutic area with potential acquirer profile.

6Eisai
TypeBroad incumbent
Description

Global pharmaceutical company with a strong neurology franchise including the epilepsy treatment Fycompa (perampanel). Comparable as an established player with deep epilepsy commercial reach.

TypeDirect peer
Description

Specialty CNS pharmaceutical company with a focused epilepsy franchise (e.g., cenobamate/XCOPRI). Directly comparable as a neurology-focused company targeting the same patient population as Engage.

TypeBroad incumbent
Description

Global biopharmaceutical company with an established neurology franchise including epilepsy treatments (e.g., Epidiolex). Comparable to Engage as a larger player in the same therapeutic space with overlapping target indications.

TypeRegional player
Description

Portuguese pharmaceutical company with a focused neurology franchise including epilepsy (e.g., Zebinix). Comparable as a smaller, neurology-focused peer with established epilepsy commercial infrastructure in select geographies.

TypeBroad incumbent
Description

Global pharmaceutical company specializing in brain diseases, including epilepsy. Comparable as a neurology-focused incumbent with potential strategic interest in Engage's therapeutic area.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Engage Therapeutics

Epilepsy Therapeuticsengagetherapeutics.com

Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 in Summit, New Jersey, developing treatments for epilepsy. The privately held firm has raised $23.6M in venture capital led by TPG Biotech.

What Engage Therapeutics does

Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 and headquartered in Summit, New Jersey. The company is focused on developing therapeutic solutions for epilepsy, operating within the broader neurological and autoimmune drug development space. Per the firmographic data, Engage Therapeutics runs a deliberately lean organization of 1-10 employees, consistent with a venture-backed, asset-focused biotech structure.

The company was capitalized at founding by a $23.6 million venture financing closed in September 2017, led by TPG Biotech with participation from Adage Capital Management, Granite Point Capital, LifeSci Venture Partners, and Lumira Ventures. The founding executive team consists of Greg Mayes as President, CEO, and Founder, with Heath Lukatch serving as Chairman. The company remains privately held, and no commercial products, pricing, partnerships, or revenue figures specific to Engage Therapeutics are disclosed in the available input data.

Note on data hygiene: a substantial portion of the input aggregates material pertaining to UCB S.A., a publicly traded Belgian biopharmaceutical company with operations across dozens of countries. That material — including UCB's revenue disclosures, global footprint, Candid Therapeutics acquisition, UCBCares service, and sub-brand portfolio — describes a separate entity and is not attributable to Engage Therapeutics in this analysis.

Engage Therapeutics firmographics

Firmographics
Name
Engage Therapeutics
Legal name
UCB S.A.
Website
https://engagetherapeutics.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 in Summit, New Jersey, developing treatments for epilepsy. The privately held firm has raised $23.6M in venture capital led by TPG Biotech.
Ownership category
akta.pro rank

Engage Therapeutics industry classification

Industry
Product category
Epilepsy Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAIAB
Epilepsy & Seizure Disorders

Keywords

  • Clinical stage pharmaceuticals
  • Epilepsy drug development
  • Neurology therapeutics
  • Biopharmaceutical research
  • Seizure treatment development

Where Engage Therapeutics is headquartered

Location

Headquarters

HQ city
Summit
HQ country
United States
HQ region
North America

Markets served

Engage Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels7 records

Engage Therapeutics product offering

Product offering

Core offering

Engage Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic drug candidates for epilepsy. The company focuses on advancing treatments for seizure management through clinical development of neurological therapies, operating from its Summit, New Jersey headquarters with a small team (1-10 employees).

Differentiator

Problem solved

Functional benefit

Brands

  • UCBCares: A personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine
  • UCB Ventures
  • UCB Community Health Fund

Products and services

  • Epilepsy Clinical Development Program Clinical-stage drug development program advancing therapeutic candidates for the treatment of epilepsy and seizure-related neurological conditions. Targeted at patients living with severe seizure disorders; the program operates at a pre-commercial, clinical-stage phase with therapeutic candidates advancing through clinical development.

Companies that use Engage Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Engage Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Engage Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Candid TherapeuticscoreStrategic or Co-development Partner · 1 January 2026UCB completed acquisition of Candid Therapeutics to strengthen its next-generation immunology pipeline. This strategic acquisition enhances UCB's immunology portfolio and research capabilities.

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Engage Therapeutics competitors and assessment

Company assessment

Direct peers

  • Xenon Pharmaceuticals: Clinical-stage neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy and other neurological conditions. Comparable to Engage in therapeutic area and clinical development stage.
  • Marinus Pharmaceuticals: Clinical-stage CNS biopharmaceutical company focused on seizure disorders, including status epilepticus and rare epilepsies. Directly comparable to Engage in therapeutic area, development stage, and target patient population.
  • Longboard Pharmaceuticals: Clinical-stage biopharmaceutical company developing transformative medicines for neurological diseases, with a focus on rare and severe epilepsies. Closely comparable to Engage in stage, therapeutic focus, and capital structure.
  • SK Life Science: Specialty CNS pharmaceutical company with a focused epilepsy franchise (e.g., cenobamate/XCOPRI). Directly comparable as a neurology-focused company targeting the same patient population as Engage.

Broad incumbents

  • Pfizer: Global pharmaceutical company with a historical epilepsy franchise (e.g., Lyrica, Neurontin) and broad CNS capabilities. Comparable as a large pharma incumbent with neurology depth and acquirer potential.
  • UCB: Global biopharmaceutical leader with major epilepsy franchise (Vimpat, Keppra) and broad CNS pipeline. Comparable as a large incumbent in Engage's therapeutic area with potential acquirer profile.
  • Eisai: Global pharmaceutical company with a strong neurology franchise including the epilepsy treatment Fycompa (perampanel). Comparable as an established player with deep epilepsy commercial reach.
  • Jazz Pharmaceuticals: Global biopharmaceutical company with an established neurology franchise including epilepsy treatments (e.g., Epidiolex). Comparable to Engage as a larger player in the same therapeutic space with overlapping target indications.
  • Lundbeck: Global pharmaceutical company specializing in brain diseases, including epilepsy. Comparable as a neurology-focused incumbent with potential strategic interest in Engage's therapeutic area.

Regional players

  • BIAL: Portuguese pharmaceutical company with a focused neurology franchise including epilepsy (e.g., Zebinix). Comparable as a smaller, neurology-focused peer with established epilepsy commercial infrastructure in select geographies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Engage Therapeutics social profiles

Digital presence

Engage Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Engage Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Engage Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Engage Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Engage Therapeutics

What does Engage Therapeutics do?

Engage Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic drug candidates for epilepsy. The company focuses on advancing treatments for seizure management through clinical development of neurological therapies, operating from its Summit, New Jersey headquarters with a small team (1-10 employees).

Is Engage Therapeutics a public or private company?

Engage Therapeutics is a public company. It is classified as venture growth investor backed and is currently operating.

When was Engage Therapeutics founded?

Engage Therapeutics was founded in 2007. It employs 1 to 10 people.

Where is Engage Therapeutics based?

Engage Therapeutics is headquartered in Summit, United States, in the North America region.

Who are Engage Therapeutics's main competitors?

Direct peers on record are Xenon Pharmaceuticals, Marinus Pharmaceuticals, Longboard Pharmaceuticals and SK Life Science. Broad incumbents are Pfizer, UCB, Eisai, Jazz Pharmaceuticals and Lundbeck. BIAL is listed as a regional player.

Does Engage Therapeutics have an API?

No public API is recorded for Engage Therapeutics.

What industry is Engage Therapeutics in?

Engage Therapeutics's product category is Epilepsy Therapeutics. Its primary akta.pro industry code is HLAKAIAB, Epilepsy & Seizure Disorders. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NJBIZStill the Medicine Chest of the WorldNew Jersey's pharmaceutical and biotech industries remain strong, attracting new companies despite some departures. The state offers incentives, talent, and infrastructure, with over half of the world's top 40 life sciences companies based there. Companies like Scynexis and Engage Therapeutics cite these advantages for relocation.GlobeNewswireBestselling Author Kurt Eichenwald to Lead Inspiring Discussion about Epilepsy and his Memior, ‘A Mind Unraveled’ Thursday, July 11, at 7 p.m. at Mayfair Hotel and SpaKurt Eichenwald will discuss his memoir 'A Mind Unraveled' about his epilepsy at the Mayfair Hotel and Spa on July 11. The free event is sponsored by Engage Therapeutics, which is developing Staccato alprazolam, a hand-held inhaler for seizure rescue. The company is also conducting a multi-center StATES study.GlobeNewswireEngage Therapeutics and Clinical Trial Network of Houston Host New York Times Bestselling Author Kurt Eichenwald for Inspiring Discussion about Overcoming EpilepsyKurt Eichenwald will discuss his memoir 'A Mind Unraveled' at a free event in Houston on June 13, sponsored by Engage Therapeutics and the Clinical Trial Network of Houston. The companies are collaborating on a phase 2b trial of Staccato alprazolam, a hand-held inhaler for stopping seizures, with about 50 trial sites.NJBIZBiotech startups selected to accompany NJEDA to Bio InternationalNJEDA selected five New Jersey biotech startups to join it at BIO International in Philadelphia next month. The companies, including 3D Biotek, Engage Therapeutics, Socium Therapeutics, OncoSec, and Tyme Technologies, were chosen for their proximity to pharmaceutical firms and affordable lab space. The event runs June 3-6 with over 16,000 attendees.GlobeNewswireEngage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled PortionEngage Therapeutics announced completion of the open-label portion of its Phase 2b StATES study on Staccato alprazolam for epilepsy, with enrollment now starting in the double-blind placebo-controlled portion. The trial will present results at a major medical meeting in 2019, and 100 subjects are needed for the double-blind portion, expected to finish in the second half of 2019.PR NewswireOncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of DirectorsOncoSec Medical Incorporated appointed Gregory T. Mayes to its board of directors on January 12, 2018. Mayes brings over 20 years of biopharmaceutical executive experience and currently serves as President, CEO, and Founder of Engage Therapeutics. He stated he looks forward to contributing to the advancement of OncoSec's ImmunoPulse intratumoral immunotherapy platform.